17753 Analysis of 24-week response to ruxolitinib cream for the treatment of vitiligo based on patient demographics and clinical characteristics

Document Type

Conference Proceeding

Publication Date


Publication Title

J Am Acad Dermatol


Ruxolitinib cream, a Janus kinase inhibitor, is under investigation for vitiligo treatment. Factors including skin type and disease duration may contribute to treatment efficacy. This 24-week component of a 104-week, phase 2, randomized, double-blind study (NCT03099304) enrolled adult patients with vitiligo that included depigmentation ≥0.5% of body surface area (BSA) on the face and ≥3% of BSA on nonfacial areas. 157 patients were equally randomized to receive ruxolitinib cream (1.5% twice daily [bid], 1.5% once daily [QD], 0.5% QD, or 0.15% QD) or vehicle bid for 24 weeks. The primary end point was the proportion of patients achieving ≥50% improvement in facial Vitiligo Area Scoring Index (F-VASI50) at week 24. This subgroup analysis investigated response by patient demographics and baseline characteristics; results were generally similar across treatment groups at week 24. Among patients who received ruxolitinib cream 1.5% BID (n = 33; F-VASI50 responders, 45.5%), a larger proportion of patients in the following subgroups were F-VASI50 responders: patients ≤50 years old (58.8%); female patients (60.0%); patients with skin type I–III (50.0%), ≤1.5% affected baseline facial, BSA (52.6%), baseline F-VASI scores of 0.75 to 20 years (60.0%); and previous recipients of topical corticosteroids (50.0%). There were no substantial differences between responders who were white (44.8%) vs nonwhite (50.0%), who had stable (46.2%) vs progressive disease (45.0%), or those with total, BSA ≤20% (45.0%) vs >20% (46.2%). Ruxolitinib cream was effective for the treatment of vitiligo across demographics and clinical characteristics, including in patients with longstanding and extensive disease.





First Page


This document is currently not available here.